- Home
- GOSS vs NKTX Comparison
GOSS vs NKTX Comparison
Compare GOSS & NKTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GOSS
- NKTX
- Stock Information
- Founded
- GOSS 2015
- NKTX 2015
- Country
- GOSS United States
- NKTX United States
- Employees
- GOSS N/A
- NKTX N/A
- Industry
- GOSS Biotechnology: Pharmaceutical Preparations
- NKTX Biotechnology: Pharmaceutical Preparations
- Sector
- GOSS Health Care
- NKTX Health Care
- Exchange
- GOSS Nasdaq
- NKTX Nasdaq
- Market Cap
- GOSS 212.8M
- NKTX 170.8M
- IPO Year
- GOSS 2019
- NKTX 2020
- Fundamental
- Price
- GOSS $1.27
- NKTX $1.48
- Analyst Decision
- GOSS Strong Buy
- NKTX Strong Buy
- Analyst Count
- GOSS 5
- NKTX 5
- Target Price
- GOSS $9.20
- NKTX $15.20
- AVG Volume (30 Days)
- GOSS 1.5M
- NKTX 940.8K
- Earning Date
- GOSS 03-13-2025
- NKTX 05-08-2025
- Dividend Yield
- GOSS N/A
- NKTX N/A
- EPS Growth
- GOSS N/A
- NKTX N/A
- EPS
- GOSS N/A
- NKTX N/A
- Revenue
- GOSS $114,701,000.00
- NKTX N/A
- Revenue This Year
- GOSS N/A
- NKTX N/A
- Revenue Next Year
- GOSS $154.71
- NKTX N/A
- P/E Ratio
- GOSS N/A
- NKTX N/A
- Revenue Growth
- GOSS N/A
- NKTX N/A
- 52 Week Low
- GOSS $0.50
- NKTX $1.42
- 52 Week High
- GOSS $1.55
- NKTX $11.84
- Technical
- Relative Strength Index (RSI)
- GOSS 51.40
- NKTX 34.14
- Support Level
- GOSS $1.27
- NKTX $1.44
- Resistance Level
- GOSS $1.48
- NKTX $1.88
- Average True Range (ATR)
- GOSS 0.11
- NKTX 0.11
- MACD
- GOSS -0.01
- NKTX -0.01
- Stochastic Oscillator
- GOSS 51.90
- NKTX 21.57
About GOSS Gossamer Bio Inc.
Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension); GB004, for the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn's disease; GB1275, for the treatment of oncology indications; and GB001, for the treatment of moderate-to-severe eosinophilic asthma.
About NKTX Nkarta Inc.
Nkarta Inc is a biopharmaceutical company engaged in developing engineered natural killer (NK) cells to treat cancer and autoimmune diseases. The Company is engaged in leveraging the natural potent power of NK cells to identify and kill abnormal cells and recruit adaptive immune effectors to generate responses that are specific and durable. The company is combining its NK expansion platform technology with proprietary cell engineering technologies to generate an abundant supply of NK cells, engineer enhanced NK cell recognition of therapeutic targets, and improve persistence for sustained activity in the body for the treatment of cancer. The Company's operations are based in South San Francisco, California.